Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Other Operating Expenses (2016 - 2025)

Amphastar Pharmaceuticals (AMPH) has 13 years of Other Operating Expenses data on record, last reported at $11.5 million in Q3 2025.

  • For Q3 2025, Other Operating Expenses rose 1.96% year-over-year to $11.5 million; the TTM value through Dec 2025 reached $23.4 million, down 38.18%, while the annual FY2025 figure was $43.9 million, 16.09% up from the prior year.
  • Other Operating Expenses reached $11.5 million in Q3 2025 per AMPH's latest filing, down from $11.9 million in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $11.9 million in Q1 2025 and bottomed at $4.1 million in Q4 2021.
  • Average Other Operating Expenses over 5 years is $7.2 million, with a median of $6.6 million recorded in 2023.
  • The widest YoY moves for Other Operating Expenses: up 76.12% in 2024, down 5.62% in 2024.
  • A 5-year view of Other Operating Expenses shows it stood at $4.1 million in 2021, then surged by 34.28% to $5.5 million in 2022, then surged by 57.51% to $8.6 million in 2023, then dropped by 5.62% to $8.1 million in 2024, then surged by 41.43% to $11.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Operating Expenses were $11.5 million in Q3 2025, $11.9 million in Q1 2025, and $8.1 million in Q4 2024.